11
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 1, 2022Recruiting
Refractory Multiple Myeloma: 1441 Clinical Trials, Page 2 of 145
Hide Studies Not Open or Pending
12
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:June 10, 2021Terminated
13
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Condition(s):Relapsed and Bortezomib Refractory Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in RelapseLast Updated:December 21, 2017Completed
14
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:May 25, 2016Completed
15
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:January 6, 2023Available
16
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 12, 2022Not yet recruiting
17
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:December 16, 2022Recruiting
18
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:November 22, 2021Completed
19
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:January 10, 2023Not yet recruiting
20
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:October 24, 2022Active, not recruiting